Search

Your search keyword '"Masetti C"' showing total 206 results
Start Over Author "Masetti C" Search Limiters Academic (Peer-Reviewed) Journals
206 results on '"Masetti C"'

1. OC.16.6: APPLICATION OF MACHINE LEARNING MODEL-3P TO PREDICT PORTAL HYPERTENSION IN PATIENT WITH HEPATOCELLULAR CARCINOMA

Author

Soleri, M., primary, Berardi, F., additional, Bertazzoni, A., additional, Fortunato, M., additional, Ceriani, R., additional, Colapietro, F., additional, Pugliese, N., additional, Masetti, C., additional, Torzilli, G., additional, Pedicini, V., additional, Poretti, D., additional, Rimassa, L., additional, Comito, T., additional, De Nalda, A. Lleo, additional, Aghemo, A.M.G., additional, and De Nicola, S., additional

Published
2024
Full Text
View/download PDF

4. High Incidence of sepsis caused by MDR bacteria in patients undergoing Percutaneous biliary drainage for the treatment of biliary obstruction

Author

De Nicola, S., primary, Cento, V., additional, Fortunato, M., additional, Masetti, C., additional, Colapietro, F., additional, Pugliese, N., additional, Ceriani, R., additional, Bianchi, I., additional, Pedicini, V., additional, Lanza, E., additional, Torzilli, G., additional, Lleo, A., additional, and Aghemo, A., additional

Published
2023
Full Text
View/download PDF

5. Prevalence and predictiors of porto-sinusoidal vascular disorder in patients with constantly elevated gamma-glutamyl transferase levels: A multicenter Italian study

Author

Pugliese, N., primary, Viganò, M., additional, Di Tommaso, L., additional, Maggioni, M., additional, Cerini, F., additional, Santopaolo, F., additional, Bianco, C., additional, Masetti, C., additional, Lleo, A., additional, Manini, M.A., additional, Valenti, L., additional, Giustiniani, M.C., additional, Ponziani, F.R., additional, Terracciano, L., additional, and Aghemo, A., additional

Published
2023
Full Text
View/download PDF

6. OC.12.5 MYOSTEATOSIS IS NOT ASSOCIATED WITH COMPLICATIONS OR SURVIVAL IN HCC PATIENTS UNDERGOING TRANS ARTERIAL EMBOLIZATION

Author

De Marco, A., primary, Masetti, C., additional, Pugliese, N., additional, Lofino, L., additional, Colapietro, F., additional, Ceriani, R., additional, Lleo, A., additional, Poretti, D., additional, Pedicini, V., additional, De Nicola, S., additional, Torzilli, G., additional, Rimassa, L., additional, Aghemo, A., additional, and Lanza, E., additional

Published
2023
Full Text
View/download PDF

7. Resistance analysis and treatment outcomes in hepatitis C virus genotype 3-infected patients within the Italian network VIRONET-C

Author

Di Maio, V, Barbaliscia, S, Teti, E, Fiorentino, G, Milana, M, Paolucci, S, Pollicino, T, Morsica, G, Starace, M, Bruzzone, B, Gennari, W, Micheli, V, Yu La Rosa, K, Foroghi, L, Calvaruso, V, Lenci, I, Polilli, E, Babudieri, S, Aghemo, A, Raimondo, G, Sarmati, L, Coppola, N, Pasquazzi, C, Baldanti, F, Parruti, G, Perno, C, Angelico, M, Craxi, A, Andreoni, M, Ceccherini-Silberstein, F, Andreone, P, Aragri, M, Bertoli, A, Boeri, E, Brancaccio, G, Brunetto, M, Callegaro, A, Cenderello, G, Cento, V, Ciaccio, A, Ciancio, A, Cuomo, N, De Santis, A, Di Biagio, A, Di Marco, V, Di Perri, G, Di Stefano, M, Gaeta, G, Ghisetti, V, Gulminetti, R, Lampertico, P, Landonio, S, Lichtner, M, Lleo, A, Maida, I, Marenco, S, Masetti, C, Mastroianni, C, Minichini, C, Milano, E, Monno, L, Novati, S, Pace Palitti, V, Paternoster, C, Pellicelli, A, Pieri, A, Puoti, M, Rizzardini, G, Ruggiero, T, Rossetti, B, Sangiovanni, V, Santantonio, T, Taliani, G, Toniutto, P, Vullo, V, Zazzi, M, Di Maio V. C., Barbaliscia S., Teti E., Fiorentino G., Milana M., Paolucci S., Pollicino T., Morsica G., Starace M., Bruzzone B., Gennari W., Micheli V., Yu La Rosa K., Foroghi L., Calvaruso V., Lenci I., Polilli E., Babudieri S., Aghemo A., Raimondo G., Sarmati L., Coppola N., Pasquazzi C., Baldanti F., Parruti G., Perno C. F., Angelico M., Craxi A., Andreoni M., Ceccherini-Silberstein F., Andreone P., Aragri M., Bertoli A., Boeri E., Brancaccio G., Brunetto M., Callegaro A. P., Cenderello G., Cento V., Ciaccio A., Ciancio A., Cuomo N., De Santis A., Di Biagio A., Di Marco V., Di Perri G., Di Stefano M. A., Gaeta G. B., Ghisetti V., Gulminetti R., Lampertico P., Landonio S., Lichtner M., Lleo A., Maida I., Marenco S., Masetti C., Mastroianni C., Minichini C., Milano E., Monno L., Novati S., Pace Palitti V., Paternoster C., Pellicelli A., Pieri A., Puoti M., Rizzardini G., Ruggiero T., Rossetti B., Sangiovanni V., Santantonio T., Taliani G., Toniutto P., Vullo V., Zazzi M., Di Maio, V, Barbaliscia, S, Teti, E, Fiorentino, G, Milana, M, Paolucci, S, Pollicino, T, Morsica, G, Starace, M, Bruzzone, B, Gennari, W, Micheli, V, Yu La Rosa, K, Foroghi, L, Calvaruso, V, Lenci, I, Polilli, E, Babudieri, S, Aghemo, A, Raimondo, G, Sarmati, L, Coppola, N, Pasquazzi, C, Baldanti, F, Parruti, G, Perno, C, Angelico, M, Craxi, A, Andreoni, M, Ceccherini-Silberstein, F, Andreone, P, Aragri, M, Bertoli, A, Boeri, E, Brancaccio, G, Brunetto, M, Callegaro, A, Cenderello, G, Cento, V, Ciaccio, A, Ciancio, A, Cuomo, N, De Santis, A, Di Biagio, A, Di Marco, V, Di Perri, G, Di Stefano, M, Gaeta, G, Ghisetti, V, Gulminetti, R, Lampertico, P, Landonio, S, Lichtner, M, Lleo, A, Maida, I, Marenco, S, Masetti, C, Mastroianni, C, Minichini, C, Milano, E, Monno, L, Novati, S, Pace Palitti, V, Paternoster, C, Pellicelli, A, Pieri, A, Puoti, M, Rizzardini, G, Ruggiero, T, Rossetti, B, Sangiovanni, V, Santantonio, T, Taliani, G, Toniutto, P, Vullo, V, Zazzi, M, Di Maio V. C., Barbaliscia S., Teti E., Fiorentino G., Milana M., Paolucci S., Pollicino T., Morsica G., Starace M., Bruzzone B., Gennari W., Micheli V., Yu La Rosa K., Foroghi L., Calvaruso V., Lenci I., Polilli E., Babudieri S., Aghemo A., Raimondo G., Sarmati L., Coppola N., Pasquazzi C., Baldanti F., Parruti G., Perno C. F., Angelico M., Craxi A., Andreoni M., Ceccherini-Silberstein F., Andreone P., Aragri M., Bertoli A., Boeri E., Brancaccio G., Brunetto M., Callegaro A. P., Cenderello G., Cento V., Ciaccio A., Ciancio A., Cuomo N., De Santis A., Di Biagio A., Di Marco V., Di Perri G., Di Stefano M. A., Gaeta G. B., Ghisetti V., Gulminetti R., Lampertico P., Landonio S., Lichtner M., Lleo A., Maida I., Marenco S., Masetti C., Mastroianni C., Minichini C., Milano E., Monno L., Novati S., Pace Palitti V., Paternoster C., Pellicelli A., Pieri A., Puoti M., Rizzardini G., Ruggiero T., Rossetti B., Sangiovanni V., Santantonio T., Taliani G., Toniutto P., Vullo V., and Zazzi M.

Abstract

Aim: This study aimed to investigate the role of resistance-associated substitutions (RASs) to direct-acting-antivirals (DAAs) in HCV genotype 3 (GT3). Methods: Within the Italian VIRONET-C network, a total of 539 GT3-infected patients (417 DAA-naïve and 135 DAA-failures, of them, 13 at both baseline and failure) were analysed. Sanger sequencing of NS3/NS5A/NS5B was performed following home-made protocols. Results: The majority of patients were male (79.4%), 91.4% were injection drug users, 49.3% were cirrhotic and 13.9% were HIV co-infected. Phylogenetic analysis classified sequences as GT3a-b-g-h (98%-0.4%-0.2%-1.2%) respectively. Overall, 135 patients failed a DAA regimen: sofosbuvir (SOF)/daclatasvir (DCV) or velpatasvir (VEL)±ribavirin (RBV) (N = 91/15) and glecaprevir (G)/pibrentasvir (P) (N = 9). Moreover, 14.8% of patients were treated with suboptimal regimens for GT3: 3D ± RBV (Paritaprevir/r + Ombitasvir+Dasabuvir, N = 15), SOF + Simeprevir (SIM) (N = 1) or SOF/Ledipasvir (LDV) ± RBV (N = 4). RAS prevalence was 15.8% in DAA-naïve patients. At failure, 81.5% patients showed at least one RAS: 11/25 (44.0%) in NS3, 109/135 (80.7%) in NS5A, 7/111 (6.3%) in NS5B SOF-failures. In NS5A-failures, Y93H RAS was the most prevalent (68.5% vs 5.1% DAA-naïve, P <.001) followed by A30K (12.7% vs 2.8% in DAA-naïve, P <.001). Analysing baseline samples, a higher prevalence of NS5A-RASs was observed before treatment in DAA-failures (5/13, 38.5%) vs DAA-naïves (61/393, 15.5%, P =.04). Regarding 228 DAA-naïve patients with an available outcome, 93.9% achieved a SVR. Interestingly, patients with baseline Y93H and/or A30K had SVR rate of 72.2% vs 95.7% for patients without NS5A-RASs (P =.002). Conclusions: In this real-life GT3 cohort, the majority of failures harboured resistant variants carrying NS5A-RASs, the most frequent being Y93H. The presence of natu

Published
2021

9. Resistance analysis and treatment outcomes in hepatitis C virus genotype 3-infected patients within the Italian network VIRONET-C

Author

Di Maio, V. C., Barbaliscia, S., Teti, E., Fiorentino, G., Milana, M., Paolucci, S., Pollicino, T., Morsica, G., Starace, M., Bruzzone, B., Gennari, W., Micheli, V., Yu La Rosa, K., Foroghi, L., Calvaruso, V., Lenci, I., Polilli, E., Babudieri, S., Aghemo, A., Raimondo, G., Sarmati, L., Coppola, N., Pasquazzi, C., Baldanti, F., Parruti, G., Perno, C. F., Angelico, M., Craxi, A., Andreoni, M., Ceccherini-Silberstein, F., Andreone, P., Aragri, M., Bertoli, A., Boeri, E., Brancaccio, G., Brunetto, M., Callegaro, A. P., Cenderello, G., Cento, V., Ciaccio, A., Ciancio, A., Cuomo, N., De Santis, A., Di Biagio, A., Di Marco, V., Di Perri, G., Di Stefano, M. A., Gaeta, G. B., Ghisetti, V., Gulminetti, R., Lampertico, P., Landonio, S., Lichtner, M., Lleo, A., Maida, I., Marenco, S., Masetti, C., Mastroianni, C., Minichini, C., Milano, E., Monno, L., Novati, S., Pace Palitti, V., Paternoster, C., Pellicelli, A., Pieri, A., Puoti, M., Rizzardini, G., Ruggiero, T., Rossetti, B., Sangiovanni, V., Santantonio, T., Taliani, G., Toniutto, P., Vullo, V., Zazzi, M., Di Maio, V, Barbaliscia, S, Teti, E, Fiorentino, G, Milana, M, Paolucci, S, Pollicino, T, Morsica, G, Starace, M, Bruzzone, B, Gennari, W, Micheli, V, Yu La Rosa, K, Foroghi, L, Calvaruso, V, Lenci, I, Polilli, E, Babudieri, S, Aghemo, A, Raimondo, G, Sarmati, L, Coppola, N, Pasquazzi, C, Baldanti, F, Parruti, G, Perno, C, Angelico, M, Craxi, A, Andreoni, M, Ceccherini-Silberstein, F, Andreone, P, Aragri, M, Bertoli, A, Boeri, E, Brancaccio, G, Brunetto, M, Callegaro, A, Cenderello, G, Cento, V, Ciaccio, A, Ciancio, A, Cuomo, N, De Santis, A, Di Biagio, A, Di Marco, V, Di Perri, G, Di Stefano, M, Gaeta, G, Ghisetti, V, Gulminetti, R, Lampertico, P, Landonio, S, Lichtner, M, Lleo, A, Maida, I, Marenco, S, Masetti, C, Mastroianni, C, Minichini, C, Milano, E, Monno, L, Novati, S, Pace Palitti, V, Paternoster, C, Pellicelli, A, Pieri, A, Puoti, M, Rizzardini, G, Ruggiero, T, Rossetti, B, Sangiovanni, V, Santantonio, T, Taliani, G, Toniutto, P, Vullo, V, Zazzi, M, Di Maio, Vc, Perno, Cf, Craxì, A, Di Maio V.C., Barbaliscia S., Teti E., Fiorentino G., Milana M., Paolucci S., Pollicino T., Morsica G., Starace M., Bruzzone B., Gennari W., Micheli V., Yu La Rosa K., Foroghi L., Calvaruso V., Lenci I., Polilli E., Babudieri S., Aghemo A., Raimondo G., Sarmati L., Coppola N., Pasquazzi C., Baldanti F., Parruti G., Perno C.F., Angelico M., Craxi A., Andreoni M., Ceccherini-Silberstein F., Andreone P., Aragri M., Bertoli A., Boeri E., Brancaccio G., Brunetto M., Callegaro A.P., Cenderello G., Cento V., Ciaccio A., Ciancio A., Cuomo N., De Santis A., Di Biagio A., Di Marco V., Di Perri G., Di Stefano M.A., Gaeta G.B., Ghisetti V., Gulminetti R., Lampertico P., Landonio S., Lichtner M., Lleo A., Maida I., Marenco S., Masetti C., Mastroianni C., Minichini C., Milano E., Monno L., Novati S., Pace Palitti V., Paternoster C., Pellicelli A., Pieri A., Puoti M., Rizzardini G., Ruggiero T., Rossetti B., Sangiovanni V., Santantonio T., Taliani G., Toniutto P., Vullo V., and Zazzi M.

Subjects
Male, Sofosbuvir, Sustained Virologic Response, Drug Resistance, Hepacivirus, Viral Nonstructural Proteins, Gastroenterology, Settore MED/06, direct-acting antivirals, failure, genotype 3, HCV, resistance, chemistry.chemical_compound, 0302 clinical medicine, Medicine, Viral, Chronic, Phylogeny, Dasabuvir, hcv, virus diseases, Hepatitis C, Pibrentasvir, Italy, 030220 oncology & carcinogenesis, Combination, Drug Therapy, Combination, 030211 gastroenterology & hepatology, Female, medicine.drug, Ledipasvir, medicine.medical_specialty, Daclatasvir, Genotype, Antiviral Agents, Drug Resistance, Viral, Humans, Hepatitis C, Chronic, 03 medical and health sciences, Drug Therapy, Internal medicine, Antiviral Agent, direct-acting antiviral, Hepaciviru, Hepatology, business.industry, Viral Nonstructural Protein, Glecaprevir, direct acting antivirals, Regimen, chemistry, Paritaprevir, business
Abstract

Aim: This study aimed to investigate the role of resistance-associated substitutions (RASs) to direct-acting-antivirals (DAAs) in HCV genotype 3 (GT3). Methods: Within the Italian VIRONET-C network, a total of 539 GT3-infected patients (417 DAA-naïve and 135 DAA-failures, of them, 13 at both baseline and failure) were analysed. Sanger sequencing of NS3/NS5A/NS5B was performed following home-made protocols. Results: The majority of patients were male (79.4%), 91.4% were injection drug users, 49.3% were cirrhotic and 13.9% were HIV co-infected. Phylogenetic analysis classified sequences as GT3a-b-g-h (98%-0.4%-0.2%-1.2%) respectively. Overall, 135 patients failed a DAA regimen: sofosbuvir (SOF)/daclatasvir (DCV) or velpatasvir (VEL)±ribavirin (RBV) (N=91/15) and glecaprevir (G)/pibrentasvir (P) (N=9). Moreover, 14.8% of patients were treated with suboptimal regimens for GT3: 3D±RBV (Paritaprevir/r+Ombitasvir+Dasabuvir, N=15), SOF+Simeprevir (SIM) (N=1) or SOF/Ledipasvir (LDV)±RBV (N=4). RAS prevalence was 15.8% in DAA-naïve patients. At failure, 81.5% patients showed at least one RAS: 11/25 (44.0%) in NS3, 109/135 (80.7%) in NS5A, 7/111 (6.3%) in NS5B SOF-failures. In NS5A-failures, Y93H RAS was the most prevalent (68.5% vs 5.1% DAA-naïve, P&nbsp

Published
2021

10. High rates of histological findings compatible with porto-sinusoidal vascular liver disease in patients with constantly elevated gamma-glutamyl transferase levels undergoing a liver biopsy

Author

Pugliese, N., primary, Di Tommaso, L., additional, Ceriani, R., additional, Alfarone, L., additional, Mastrorocco, E., additional, Terrin, M., additional, Solitano, V., additional, Masetti, C., additional, Colapietro, F., additional, Lleo, A., additional, Terracciano, L., additional, and Aghemo, A., additional

Published
2022
Full Text
View/download PDF

14. Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1-4 in Italy

Author

Bertoli, A, Sorbo, M, Aragri, M, Lenci, I, Teti, E, Polilli, E, Di Maio, V, Gianserra, L, Biliotti, E, Masetti, C, Magni, C, Babudieri, S, Nicolini, L, Milana, M, Cacciatore, P, Sarmati, L, Pellicelli, A, Paolucci, S, Craxi, A, Morisco, F, Palitti, V, Siciliano, M, Coppola, N, Iapadre, N, Puoti, M, Rizzardini, G, Taliani, G, Pasquazzi, C, Andreoni, M, Parruti, G, Angelico, M, Perno, C, Cento, V, Ceccherini-Silberstein, F, Andreone, P, Baldanti, F, Barbarini, G, Boccaccio, V, Boglione, L, Bolis, M, Bonora, S, Borghi, V, Brancaccio, G, Bruno, S, Bruzzone, B, Calvaruso, V, Caporaso, N, Ciaccio, A, Ciancio, A, Colombatto, P, Cozzolongo, R, D'Ambrosio, C, D'Ettorre, G, De Leonardis, F, De Luca, A, Di Biagio, A, Di Perri, G, Francioso, S, Gaeta, G, Gasbarrini, A, Ghisetti, V, Giorgini, A, Grieco, A, Gubertini, G, Gulminetti, R, Lambiase, L, Landonio, S, Lichtner, M, Maida, I, Marenco, S, Marinaro, L, Maserati, R, Melis, M, Menzaghi, B, Meregalli, E, Micheli, V, Niero, F, Paoloni, M, Pieri, A, Rendina, M, Romagnoli, D, Rossetti, B, Ruggiero, T, Sangiovanni, V, Starace, M, Sticchi, L, Tarquini, P, Toniutto, P, Vullo, V, Zazzi, M, Bertoli A., Sorbo M. C., Aragri M., Lenci I., Teti E., Polilli E., Di Maio V. C., Gianserra L., Biliotti E., Masetti C., Magni C. F., Babudieri S., Nicolini L. A., Milana M., Cacciatore P., Sarmati L., Pellicelli A., Paolucci S., Craxi A., Morisco F., Palitti V. P., Siciliano M., Coppola N., Iapadre N., Puoti M., Rizzardini G., Taliani G., Pasquazzi C., Andreoni M., Parruti G., Angelico M., Perno C. F., Cento V., Ceccherini-Silberstein F., Andreone P., Baldanti F., Barbarini G., Boccaccio V., Boglione L., Bolis M., Bonora S., Borghi V., Brancaccio G., Bruno S., Bruzzone B., Calvaruso V., Caporaso N., Ciaccio A., Ciancio A., Colombatto P., Cozzolongo R., D'Ambrosio C., D'Ettorre G., De Leonardis F., De Luca A., Di Biagio A., Di Perri G., Francioso S., Gaeta G. B., Gasbarrini A., Ghisetti V., Giorgini A., Grieco A., Gubertini G., Gulminetti R., Lambiase L., Landonio S., Lichtner M., Maida I., Marenco S., Marinaro L., Maserati R., Melis M., Menzaghi B., Meregalli E., Micheli V., Niero F., Paoloni M., Pieri A., Rendina M., Romagnoli D., Rossetti B., Ruggiero T., Sangiovanni V., Starace M., Sticchi L., Tarquini P., Toniutto P., Vullo V., Zazzi M., Bertoli, A, Sorbo, M, Aragri, M, Lenci, I, Teti, E, Polilli, E, Di Maio, V, Gianserra, L, Biliotti, E, Masetti, C, Magni, C, Babudieri, S, Nicolini, L, Milana, M, Cacciatore, P, Sarmati, L, Pellicelli, A, Paolucci, S, Craxi, A, Morisco, F, Palitti, V, Siciliano, M, Coppola, N, Iapadre, N, Puoti, M, Rizzardini, G, Taliani, G, Pasquazzi, C, Andreoni, M, Parruti, G, Angelico, M, Perno, C, Cento, V, Ceccherini-Silberstein, F, Andreone, P, Baldanti, F, Barbarini, G, Boccaccio, V, Boglione, L, Bolis, M, Bonora, S, Borghi, V, Brancaccio, G, Bruno, S, Bruzzone, B, Calvaruso, V, Caporaso, N, Ciaccio, A, Ciancio, A, Colombatto, P, Cozzolongo, R, D'Ambrosio, C, D'Ettorre, G, De Leonardis, F, De Luca, A, Di Biagio, A, Di Perri, G, Francioso, S, Gaeta, G, Gasbarrini, A, Ghisetti, V, Giorgini, A, Grieco, A, Gubertini, G, Gulminetti, R, Lambiase, L, Landonio, S, Lichtner, M, Maida, I, Marenco, S, Marinaro, L, Maserati, R, Melis, M, Menzaghi, B, Meregalli, E, Micheli, V, Niero, F, Paoloni, M, Pieri, A, Rendina, M, Romagnoli, D, Rossetti, B, Ruggiero, T, Sangiovanni, V, Starace, M, Sticchi, L, Tarquini, P, Toniutto, P, Vullo, V, Zazzi, M, Bertoli A., Sorbo M. C., Aragri M., Lenci I., Teti E., Polilli E., Di Maio V. C., Gianserra L., Biliotti E., Masetti C., Magni C. F., Babudieri S., Nicolini L. A., Milana M., Cacciatore P., Sarmati L., Pellicelli A., Paolucci S., Craxi A., Morisco F., Palitti V. P., Siciliano M., Coppola N., Iapadre N., Puoti M., Rizzardini G., Taliani G., Pasquazzi C., Andreoni M., Parruti G., Angelico M., Perno C. F., Cento V., Ceccherini-Silberstein F., Andreone P., Baldanti F., Barbarini G., Boccaccio V., Boglione L., Bolis M., Bonora S., Borghi V., Brancaccio G., Bruno S., Bruzzone B., Calvaruso V., Caporaso N., Ciaccio A., Ciancio A., Colombatto P., Cozzolongo R., D'Ambrosio C., D'Ettorre G., De Leonardis F., De Luca A., Di Biagio A., Di Perri G., Francioso S., Gaeta G. B., Gasbarrini A., Ghisetti V., Giorgini A., Grieco A., Gubertini G., Gulminetti R., Lambiase L., Landonio S., Lichtner M., Maida I., Marenco S., Marinaro L., Maserati R., Melis M., Menzaghi B., Meregalli E., Micheli V., Niero F., Paoloni M., Pieri A., Rendina M., Romagnoli D., Rossetti B., Ruggiero T., Sangiovanni V., Starace M., Sticchi L., Tarquini P., Toniutto P., Vullo V., and Zazzi M.

Abstract

Natural resistance-associated substitutions (RASs) are reported with highly variable prevalence across different HCV genotypes (GTs). Frequency of natural RASs in a large Italian real-life cohort of patients infected with the 4 main HCV-GTs was investigated. NS3, NS5A and NS5B sequences were analysed in 1445 HCV-infected DAA-naïve patients. Sanger-sequencing was performed by home-made protocols on 464 GT1a, 585 GT1b, 92 GT2c, 199 GT3a, 16 GT4a and 99 GT4d samples. Overall, 20.7% (301/1455) of patients showed natural RASs, and the prevalence of multiclass-resistance was 7.3% (29/372 patients analysed). NS3-RASs were particularly common in GT1a and GT1b (45.2-10.8%, respectively), mainly due to 80K presence in GT1a (17%). Almost all GTs showed high prevalence of NS5A-RASs (range: 10.2-45.4%), and especially of 93H (5.1%). NS5A-RASs with fold-change >100x were detected in 6.8% GT1a (30H/R-31M-93C/H), 10.3% GT1b (31V-93H), 28.4% GT2c (28C-31M-93H), 8.5% GT3a (30K-93H), 45.5% GT4a (28M-30R-93H) and 3.8% GT4d (28V-30S-93H). Sofosbuvir RAS 282T was never detected, while the 159F and 316N RASs were found in GT1b (13.4-19.1%, respectively). Natural RASs are common in Italian patients infected with HCV-GTs 1-4. High prevalence of clinically-relevant RASs (such as Y93H) supports the appropriateness of HCV resistance-test to properly guide DAA-based therapy.

Published
2018

15. Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens?

Author

Di Maio, V, Cento, V, Aragri, M, Paolucci, S, Pollicino, T, Coppola, N, Bruzzone, B, Ghisetti, V, Zazzi, M, Brunetto, M, Bertoli, A, Barbaliscia, S, Galli, S, Gennari, W, Baldanti, F, Raimondo, G, Perno, C, Ceccherini-Silberstein, F, Andreone, P, Andreoni, M, Angelico, M, Babudieri, S, Barbarini, G, Boccaccio, V, Boglione, L, Bolis, M, Bonora, S, Borghi, V, Brancaccio, G, Bruno, S, Cacciatore, P, Calvaruso, V, Caporaso, N, Ciaccio, A, Ciancio, A, Colombatto, P, Cozzolongo, R, Craxi, A, D'Ambrosio, C, D'Ettorre, G, De Luca, A, Di Biagio, A, Di Perri, G, Francioso, S, Gaeta, G, Giorgini, A, Grieco, A, Gubertini, G, Gulminetti, R, Lambiase, L, Lenci, I, Lichtner, M, Maida, I, Marenco, S, Marinaro, L, Maserati, R, Masetti, C, Melis, M, Meregalli, E, Micheli, V, Morisco, F, Niero, F, Nicolini, L, Palitti, V, Paoloni, M, Parruti, G, Pasquazzi, C, Pellicelli, A, Polilli, E, Ponti, M, Puoti, M, Rendina, M, Rizzardini, G, Rossetti, B, Ruggiero, T, Sangiovanni, V, Starace, M, Sticchi, L, Tarquini, P, Toniutto, P, Vullo, V, Di Maio V. C., Cento V., Aragri M., Paolucci S., Pollicino T., Coppola N., Bruzzone B., Ghisetti V., Zazzi M., Brunetto M., Bertoli A., Barbaliscia S., Galli S., Gennari W., Baldanti F., Raimondo G., Perno C. F., Ceccherini-Silberstein F., Andreone P., Andreoni M., Angelico M., Babudieri S., Barbarini G., Boccaccio V., Boglione L., Bolis M., Bonora S., Borghi V., Brancaccio G., Bruno S., Cacciatore P., Calvaruso V., Caporaso N., Ciaccio A., Ciancio A., Colombatto P., Cozzolongo R., Craxi A., D'Ambrosio C., D'Ettorre G., De Luca A., Di Biagio A., Di Perri G., Francioso S., Gaeta G. B., Giorgini A., Grieco A., Gubertini G., Gulminetti R., Lambiase L., Lenci I., Lichtner M., Maida I., Marenco S., Marinaro L., Maserati R., Masetti C., Melis M., Meregalli E., Micheli V., Morisco F., Niero F., Nicolini L. A., Palitti V. P., Paoloni M., Parruti G., Pasquazzi C., Pellicelli A., Polilli E., Ponti M. L., Puoti M., Rendina M., Rizzardini G., Rossetti B., Ruggiero T., Sangiovanni V., Starace M., Sticchi L., Tarquini P., Toniutto P., Vullo V., Di Maio, V, Cento, V, Aragri, M, Paolucci, S, Pollicino, T, Coppola, N, Bruzzone, B, Ghisetti, V, Zazzi, M, Brunetto, M, Bertoli, A, Barbaliscia, S, Galli, S, Gennari, W, Baldanti, F, Raimondo, G, Perno, C, Ceccherini-Silberstein, F, Andreone, P, Andreoni, M, Angelico, M, Babudieri, S, Barbarini, G, Boccaccio, V, Boglione, L, Bolis, M, Bonora, S, Borghi, V, Brancaccio, G, Bruno, S, Cacciatore, P, Calvaruso, V, Caporaso, N, Ciaccio, A, Ciancio, A, Colombatto, P, Cozzolongo, R, Craxi, A, D'Ambrosio, C, D'Ettorre, G, De Luca, A, Di Biagio, A, Di Perri, G, Francioso, S, Gaeta, G, Giorgini, A, Grieco, A, Gubertini, G, Gulminetti, R, Lambiase, L, Lenci, I, Lichtner, M, Maida, I, Marenco, S, Marinaro, L, Maserati, R, Masetti, C, Melis, M, Meregalli, E, Micheli, V, Morisco, F, Niero, F, Nicolini, L, Palitti, V, Paoloni, M, Parruti, G, Pasquazzi, C, Pellicelli, A, Polilli, E, Ponti, M, Puoti, M, Rendina, M, Rizzardini, G, Rossetti, B, Ruggiero, T, Sangiovanni, V, Starace, M, Sticchi, L, Tarquini, P, Toniutto, P, Vullo, V, Di Maio V. C., Cento V., Aragri M., Paolucci S., Pollicino T., Coppola N., Bruzzone B., Ghisetti V., Zazzi M., Brunetto M., Bertoli A., Barbaliscia S., Galli S., Gennari W., Baldanti F., Raimondo G., Perno C. F., Ceccherini-Silberstein F., Andreone P., Andreoni M., Angelico M., Babudieri S., Barbarini G., Boccaccio V., Boglione L., Bolis M., Bonora S., Borghi V., Brancaccio G., Bruno S., Cacciatore P., Calvaruso V., Caporaso N., Ciaccio A., Ciancio A., Colombatto P., Cozzolongo R., Craxi A., D'Ambrosio C., D'Ettorre G., De Luca A., Di Biagio A., Di Perri G., Francioso S., Gaeta G. B., Giorgini A., Grieco A., Gubertini G., Gulminetti R., Lambiase L., Lenci I., Lichtner M., Maida I., Marenco S., Marinaro L., Maserati R., Masetti C., Melis M., Meregalli E., Micheli V., Morisco F., Niero F., Nicolini L. A., Palitti V. P., Paoloni M., Parruti G., Pasquazzi C., Pellicelli A., Polilli E., Ponti M. L., Puoti M., Rendina M., Rizzardini G., Rossetti B., Ruggiero T., Sangiovanni V., Starace M., Sticchi L., Tarquini P., Toniutto P., and Vullo V.

Published
2018

16. Sarcopenia is common in patients with cirrhosis and unresectable HCC treated by transarterial embolization but is not associated with increased rates of complications

Author

Masetti, C., primary, Pugliese, N., additional, Messana, G., additional, Ceriani, R., additional, Poretti, D., additional, LLeo, A., additional, Lanza, E., additional, Colombo, M., additional, Personeni, N., additional, Pedicini, V., additional, Torzilli, G., additional, and Aghemo, A., additional

Published
2020
Full Text
View/download PDF

17. VIRONET-C real life experience of resistance-guided retreatment in HCV infected patients who previously failed a NS5A inhibitor-containing regimen

Author

Di Maio, V.C., primary, Aragri, M., additional, Masetti, C., additional, Paolucci, S., additional, Bruzzone, B., additional, Degasperi, E., additional, Barbaliscia, S., additional, Pollicino, T., additional, Minichini, C., additional, Calvaruso, V., additional, Rendina, M., additional, Cento, V., additional, Teti, E., additional, Micheli, V., additional, Allice, T., additional, Polilli, E., additional, Palitti, V. Pace, additional, Landonio, S., additional, Lenci, I., additional, Francioso, S., additional, Donnarumma, L., additional, Nicolini, L.A., additional, Bertoli, A., additional, Starace, M., additional, Pasquazzi, C., additional, Callegaro, A.P., additional, Morisco, F., additional, Cenderello, G., additional, Marenco, S., additional, Gulminetti, R., additional, Novati, S., additional, Scuteri, A., additional, Andreone, P., additional, Galli, S., additional, Ciancio, A., additional, Sangiovanni, V., additional, Cuomo, N., additional, Raddi, A., additional, Gennari, W., additional, Boeri, E., additional, Morsica, G., additional, Hasson, H., additional, Borghi, V., additional, Maida, I., additional, Brunetto, M., additional, Colombatto, P., additional, Cozzolongo, R., additional, De Santis, A., additional, Lichtner, M., additional, Babudieri, S., additional, Biliotti, E., additional, Taliani, G., additional, Santantonio, T., additional, Di Stefano, M., additional, Paternoster, C., additional, Ganga, R., additional, Merli, M., additional, Rizzardini, G., additional, Pellicelli, A., additional, Giannelli, V., additional, Milano, E., additional, Mastroianni, C., additional, Licata, A., additional, Di Lorenzo, F., additional, Giorgini, A., additional, Sighinolfi, L., additional, Dentone, C., additional, Lleo, A., additional, Rossetti, B., additional, Beretta, I., additional, Cariti, G., additional, Ghisetti, V., additional, Lampertico, P., additional, Parruti, G., additional, Coppola, N., additional, Baldanti, F., additional, Gaeta, G.B., additional, Raimondo, G., additional, Puoti, M., additional, Zazzi, M., additional, Andreoni, M., additional, Angelico, M., additional, Perno, C.F., additional, Craxì, A., additional, and Ceccherini-Silberstein, F., additional

Published
2020
Full Text
View/download PDF

18. DECLINE OF PREVALENCE OF RESISTANCE ASSOCIATED SUBSTITUTIONS TO NS3 AND NS5A INHIBITORS AT DAA- FAILURE IN HEPATITIS C VIRUS IN ITALY OVER THE YEARS 2015 TO 2018

Author

Redi, D., Rossetti, B., Di Maio, V. C., Aragri, M., Paolucci, S., Masetti, C., Paglicci, L., Bruzzone, B., Minichini, C., FRANCESCA MONTAGNANI, Micheli, V., Landonio, S., Degasperi, E., Giacomo Zanelli, Maserati, R., Maida, I., Callegaro, A. P., Barbaliscia, S., Bertoli, A., Paternoster, C., Marenco, S., Morisco, F., Calvaruso, V., Taliani, G., Puoti, M., Cenderello, G., Santis, A., Lichtner, M., Coppola, N., Gulminetti, R., Cento, V., Rendina, M., Teti, E., Parruti, G., Ruggiero, T., Ghisetti, V., Pasquazzi, C., Nicolini, L. A., Vullo, V., Pellicelli, A., Prestileo, T., Cozzolongo, R., Sangiovanni, V., Biolato, M., Lenci, I., Licata, A., Ciaccio, A., Pace Palitti, V., Giorgini, A., Cariti, G., Ciancio, A., Aghemo, A., Borghi, V., Andreone, P., Brunetto, M., Pollicino, T., Santantonio, T., Cuomo, N., Caudai, C., Babudieri, S., Lampertico, P., Gaeta, G. B., Raimondo, G., Andreoni, M., Rizzardini, G., Angelico, M., Perno, C. F., Craxì, A., Maurizio Zazzi, Ceccherini- Silberstein, F., and on behalf of HCV Virology Italian Resistance Network (Vironet C)

Published
2019

21. Yearly water balance of the Piedmont Alpine zone

Author

Elisa Brussolo (a), Stefanp Ferraris (b), Davide Gisolo (b), Marco Doveri (c), Giulio Masetti (c), Elisa Palazzi (d), Jost von Hardenberg (d), and Antonello Provenzale (c)

Subjects
Water balance, Piedmont Alpine zone
Abstract

Yearly water balance of the Piedmont Alpine zone

Published
2018

22. Resistance test guided retreatment of HCV infected patients with a previous failure to a NS5A inhibitor-containing regimen: the Italian Vironet C real life experience

Author

Di Maio, V.C., primary, Aragri, M., additional, Masetti, C., additional, Paolucci, S., additional, Bruzzone, B., additional, Degasperi, E., additional, Barbaliscia, S., additional, Pollicino, T., additional, Minichini, C., additional, Calvaruso, V., additional, Rendina, M., additional, Cento, V., additional, Teti, E., additional, Micheli, V., additional, Ghisetti, V., additional, Polilli, E., additional, Palitti, V. Pace, additional, Landonio, S., additional, Lenci, I., additional, Donnarumma, L., additional, Nicolini, L.A., additional, Bertoli, A., additional, Starace, M., additional, Pasquazzi, C., additional, Callegaro, A.P., additional, Morisco, F., additional, Cenderello, G., additional, Marenco, S., additional, Gulminetti, R., additional, Novati, S., additional, Guarneri, V., additional, Andreone, P., additional, Galli, S., additional, Ciancio, A., additional, Sangiovanni, V., additional, Cuomo, N., additional, Raddi, A., additional, Morsica, G., additional, Borghi, V., additional, Maida, I., additional, Brunetto, M., additional, Colombatto, P., additional, Cozzolongo, R., additional, De Santis, A., additional, Lichtner, M., additional, Babudieri, S., additional, Taliani, G., additional, Santantonio, T., additional, Di Stefano, M., additional, Paternoster, C., additional, Ganga, R., additional, Puoti, M., additional, Rizzardini, G., additional, Pellicelli, A., additional, Milano, E., additional, Mastroianni, C., additional, Licata, A., additional, Di Lorenzo, F., additional, Giorgini, A., additional, Lampertico, P., additional, Parruti, G., additional, Coppola, N., additional, Zazzi, M., additional, Raimondo, G., additional, Andreoni, M., additional, Craxì, A., additional, Angelico, M., additional, Perno, C.F., additional, and Ceccherini-Silberstein, F., additional

Published
2019
Full Text
View/download PDF

23. Characterization of baseline factors associated with treatment outcome in HCV-infected patients naive to direct acting antivirals: particular focus on natural resistance

Author

Barbaliscia, S., primary, Di Maio, V.C., additional, Teti, E., additional, Aragri, M., additional, Paolucci, S., additional, Masetti, C., additional, D’Ambrosio, R., additional, Degasperi, E., additional, Polilli, E., additional, Palitti, V. Pace, additional, Fiorentino, G., additional, Foroghi, L., additional, Cento, V., additional, Scutari, R., additional, Bruzzone, B., additional, Calvaruso, V., additional, Coppola, N., additional, Gaeta, G.B., additional, Morsica, G., additional, Ghisetti, V., additional, Bertoli, A., additional, Milana, M., additional, Nicolini, L.A., additional, Gennari, W., additional, Campoli, R., additional, Galli, S., additional, Magni, C.F., additional, Micheli, V., additional, Boccaccio, V., additional, Maserati, R., additional, Bonora, S., additional, Iapadre, N., additional, Morisco, F., additional, Siciliano, M., additional, Guarneri, V., additional, Lichtner, M., additional, Borghi, V., additional, Paba, P., additional, Sarmati, L., additional, Puoti, M., additional, Pellicelli, A., additional, Babudieri, S., additional, Rizzardini, G., additional, Taliani, G., additional, Parruti, G., additional, Lampertico, P., additional, Pasquazzi, C., additional, Angelico, M., additional, Baldanti, F., additional, Craxì, A., additional, Andreoni, M., additional, Perno, C.F., additional, and Ceccherini-Silberstein, F., additional

Published
2019
Full Text
View/download PDF

24. Overall survival and incidence of liver-related events in a cohort of cirrhotic patients treated with direct antiviral agents: results from a multicenter study

Author

Masetti, C., primary, Marignani, M., additional, Lionetti, R., additional, Gentilucci, U. Vespasiani, additional, Santopaolo, F., additional, Milana, M., additional, Begini, P., additional, Taibi, C., additional, Galati, G., additional, Comandini, U. Visco, additional, D’Offizi, G., additional, and Angelico, M., additional

Published
2019
Full Text
View/download PDF

25. MODELLI 3D E DATI GIS: UNA LORO INTEGRAZIONE PER LO STUDIO E LA VALORIZZAZIONE DEI BENI CULTURALI.

Author

Canciani, M., Saccone, M., Spadafora, G., Migliori, S., Mongelli, M., Puccini, M., Quintiliani, A., Gallia, A., and Masetti, C.

Abstract

Copyright of Archeomatica is the property of MediaGEO and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Published
2020

26. On treatment HCV-RNA evaluation in real-life: Still a role in the era of direct acting antiviral agents?

Author

Di Maio, V.C., primary, Cento, V., additional, Micheli, V., additional, Masetti, C., additional, Magni, C.F., additional, Teti, E., additional, Lenci, I., additional, Passerini, S., additional, Francioso, S., additional, Milana, M., additional, Bertoli, A., additional, Ciotti, M., additional, Aragri, M., additional, Sarmati, L., additional, Schiavini, M., additional, Gubertini, G., additional, Andreoni, M., additional, Mario, A., additional, Perno, C.F., additional, Rizzardini, G., additional, and Silberstein, F.C., additional

Published
2018
Full Text
View/download PDF

27. Lack of reduction of serum alphafetoprotein during treatment with direct antiviral agents predicts hepatocellular carcinoma development in a large cohort of patients with HCV-related cirrhosis

Author

Masetti, C., primary, Lionetti, R., additional, Lupo, M., additional, Siciliano, M., additional, Giannelli, V., additional, Ponziani, F., additional, Teti, E., additional, Dell’unto, C., additional, Francioso, S., additional, Brega, A., additional, Montalbano, M., additional, Comandini, U.V., additional, Taibi, C., additional, Galati, G., additional, Gentilucci, U.V., additional, Picardi, A., additional, Andreoni, M., additional, Pompili, M., additional, Pellicelli, A., additional, D’offizi, G., additional, Gasbarrini, A., additional, De Santis, A., additional, and Mario, A., additional

Published
2018
Full Text
View/download PDF

32. Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies

Author

Di Maio, V, Cento, V, Lenci, I, Aragri, M, Rossi, P, Barbaliscia, S, Melis, M, Verucchi, G, Magni, C, Teti, E, Bertoli, A, Antonucci, F, Bellocchi, M, Micheli, V, Masetti, C, Landonio, S, Francioso, S, Santopaolo, F, Pellicelli, A, Calvaruso, V, Gianserra, L, Siciliano, M, Romagnoli, D, Cozzolongo, R, Grieco, A, Morisco, F, Merli, M, Brancaccio, G, Di Biagio, A, Loggi, E, Mastroianni, C, Pace Palitti, V, Tarquini, P, Puoti, M, Taliani, G, Sarmati, L, Picciotto, A, Vullo, V, Caporaso, N, Paoloni, M, Pasquazzi, C, Rizzardini, G, Parruti, G, Craxì, A, Babudieri, S, Andreoni, M, Angelico, M, Perno, C, Ceccherini-Silberstein, F, Di Maio, V. C. a, Cento V. a, Lenci I. b, Aragri, M. a, Rossi P. b, Barbaliscia S. a, Melis M. c, Verucchi G. d, Magni, C. F. e, Teti E. f, Bertoli A, Bellocchi, MC, Pellicelli, AM, Mastroianni, CM, Perno, CF, Di Maio, V, Cento, V, Lenci, I, Aragri, M, Rossi, P, Barbaliscia, S, Melis, M, Verucchi, G, Magni, C, Teti, E, Bertoli, A, Antonucci, F, Bellocchi, M, Micheli, V, Masetti, C, Landonio, S, Francioso, S, Santopaolo, F, Pellicelli, A, Calvaruso, V, Gianserra, L, Siciliano, M, Romagnoli, D, Cozzolongo, R, Grieco, A, Morisco, F, Merli, M, Brancaccio, G, Di Biagio, A, Loggi, E, Mastroianni, C, Pace Palitti, V, Tarquini, P, Puoti, M, Taliani, G, Sarmati, L, Picciotto, A, Vullo, V, Caporaso, N, Paoloni, M, Pasquazzi, C, Rizzardini, G, Parruti, G, Craxì, A, Babudieri, S, Andreoni, M, Angelico, M, Perno, C, Ceccherini-Silberstein, F, Di Maio, V. C. a, Cento V. a, Lenci I. b, Aragri, M. a, Rossi P. b, Barbaliscia S. a, Melis M. c, Verucchi G. d, Magni, C. F. e, Teti E. f, Bertoli A, Bellocchi, MC, Pellicelli, AM, Mastroianni, CM, and Perno, CF

Abstract

Background & Aims: Despite the excellent efficacy of direct-acting antivirals (DAA) reported in clinical trials, virological failures can occur, often associated with the development of resistance-associated substitutions (RASs). This study aimed to characterize the presence of clinically relevant RASs to all classes in real-life DAA failures. Methods: Of the 200 virological failures that were analyzed in 197 DAA-treated patients, 89 with pegylated-interferon+ribavirin (PegIFN+RBV) and 111 without (HCV-1a/1b/1g/2/3/4=58/83/1/6/24/25; 56.8% treatment experienced; 65.5% cirrhotic) were observed. Sanger sequencing of NS3/NS5A/NS5B was performed by home-made protocols, at failure (N=200) and whenever possible at baseline (N=70). Results: The majority of the virological failures were relapsers (57.0%), 22.5% breakthroughs, 20.5% non-responders. RAS prevalence varied according to IFN/RBV use, DAA class, failure type and HCV genotype/subtype. It was 73.0% in IFN group vs 49.5% in IFN free, with the highest prevalence of NS5A-RASs (96.1%), compared to NS3-RASs (75.9% with IFN, 70.5% without) and NS5B-RASs (66.6% with IFN, 20.4% without, in sofosbuvir failures). In the IFN-free group, RASs were higher in breakthrough/non-responders than in relapsers (90.5% vs 40.0%, P<.001). Interestingly, 57.1% of DAA IFN-free non-responders had a misclassified genotype, and 3/4 sofosbuvir breakthroughs showed the major-RAS-S282T, while RAS-L159F was frequently found in sofosbuvir relapsers (18.2%). Notably, 9.0% of patients showed also extra target RASs, and 47.4% of patients treated with ≥2 DAA classes showed multiclass resistance, including 11/11 NS3+NS5A failures. Furthermore, 20.0% of patients had baseline-RASs, which were always confirmed at failure. Conclusions: In our failure setting, RAS prevalence was remarkably high in all genes, with a partial exception for NS5B, whose limited resistance is still higher than previously reported. This multiclass resistance advocates for HC

Published
2017

33. A different perspective on sofosbuvir-ledipasvir treatment of patients with HCV genotype 1b cirrhosis: The ital-c network study

Author

Barone, M., primary, Iannone, A., additional, Shahini, E., additional, Ippolito, A. M., additional, Brancaccio, G., additional, Morisco, F., additional, Milella, M., additional, Messina, V., additional, Smedile, A., additional, Conti, F., additional, Gatti, P., additional, Santantonio, T., additional, Tundo, P., additional, Lauletta, G., additional, Napoli, N., additional, Masetti, C., additional, Termite, A. P., additional, Francavilla, R., additional, Di Leo, A., additional, Pesce, F., additional, and Andriulli, A., additional

Published
2017
Full Text
View/download PDF

34. HCV resistance test guided retreatments after protease inhibitors failures can induce maximal efficacy rate in real-life

Author

Cento, V., primary, Barbaliscia, S., additional, Lenci, I., additional, Ruggiero, T., additional, Masetti, C., additional, Magni, C.F., additional, Micheli, V., additional, Paolucci, S., additional, Troshina, Y., additional, Biliotti, E., additional, Milana, M., additional, Melis, M., additional, Teti, E., additional, Lambiase, L., additional, Menzaghi, B., additional, Nicolini, L.A., additional, Marenco, S., additional, Di Maio, V.C., additional, Aragri, M., additional, Pecchioli, A., additional, Bertoli, A., additional, Antonucci, F.P., additional, Sarmati, L., additional, Sarrecchia, C., additional, Macera, M., additional, Coppola, N., additional, Danieli, E., additional, Romagnoli, D., additional, Pellicelli, A., additional, Bonora, S., additional, Babudieri, S., additional, Di Biagio, A., additional, Picciotto, A., additional, Novati, S., additional, Siciliano, M., additional, Messina, V., additional, Claar, E., additional, Baldanti, F., additional, Pasquazzi, C., additional, Ciancio, A., additional, Puoti, M., additional, Ghisetti, V., additional, Andreoni, M., additional, Taliani, G., additional, Rizzardini, G., additional, Angelico, M., additional, Perno, C.F., additional, and Ceccherini-Silberstein, F., additional

Published
2017
Full Text
View/download PDF

35. Natural HCV resistance is common in Italy and differently associated to genotypes

Author

Sorbo, M.C., primary, Cento, V., additional, Bertoli, A., additional, Lenci, I., additional, Polilli, E., additional, Masetti, C., additional, Gianserra, L., additional, Teti, E., additional, Biliotti, E., additional, Magni, C.F., additional, Aragri, M., additional, Micheli, V., additional, Melis, M., additional, Nicolini, L.A., additional, Marenco, S., additional, Calvaruso, V., additional, Paolucci, S., additional, Baldanti, F., additional, Morisco, F., additional, Siciliano, M., additional, Pace Palitti, V., additional, Andreone, P., additional, Bruzzone, B., additional, Coppola, N., additional, Ruggiero, T., additional, Lichtner, M., additional, Menzaghi, B., additional, Romagnoli, D., additional, Iapadre, N., additional, Di Maio, V.C., additional, De Leonardis, F., additional, Milana, M., additional, Cacciatore, P., additional, Pieri, A., additional, Sarmati, L., additional, Landonio, S., additional, Gasbarrini, A., additional, Puoti, M., additional, Craxì, A., additional, Vullo, V., additional, Pellicelli, A., additional, Babudieri, S., additional, Rizzardini, G., additional, Taliani, G., additional, Andreoni, M., additional, Pasquazzi, C., additional, Parruti, G., additional, Angelico, M., additional, Perno, C.F., additional, and Ceccherini-Silberstein, F., additional

Published
2017
Full Text
View/download PDF

36. Prevalence and characteristics of resistance associated substitutions in DAA-naive and DAA-failed HCV-3 patients in Italy

Author

Di Maio, V.C., primary, Barbaliscia, S., additional, Lenci, I., additional, Teti, E., additional, Antonucci, F.P., additional, Cento, V., additional, Aragri, M., additional, Paolucci, S., additional, Bruzzone, B., additional, Coppola, N., additional, Ruggiero, T., additional, Pollicino, T., additional, Polilli, E., additional, Pasquazzi, C., additional, Pace Palitti, V., additional, Magni, C.F., additional, Micheli, V., additional, Di Biagio, A., additional, Sticchi, L., additional, Melis, M., additional, Francioso, S., additional, Masetti, C., additional, Foroghi, L., additional, Sarrecchia, C., additional, Baiocchi, L., additional, Landonio, S., additional, Bertoli, A., additional, Calvaruso, V., additional, Morisco, F., additional, Maida, I., additional, Marenco, S., additional, Leo, A., additional, Ghisetti, V., additional, Ciancio, A., additional, Sacchi, P., additional, Novati, S., additional, Brancaccio, G., additional, Pieri, A., additional, Puoti, M., additional, Toniutto, P., additional, Vullo, V., additional, Aghemo, A., additional, Di Perri, G., additional, Babudieri, S., additional, Rizzardini, G., additional, Bruno, S., additional, Pellicelli, A., additional, Taliani, G., additional, Raimondo, G., additional, Baldanti, F., additional, Gaeta, G.B., additional, Craxì, A., additional, Parruti, G., additional, Andreoni, M., additional, Angelico, M., additional, Perno, C.F., additional, and Ceccherini-Silberstein, F., additional

Published
2017
Full Text
View/download PDF

37. Treatment with direct-acting antiviral agents is associated with improvement of renal function in a cohort of HCV-infected patients with chronic kidney disease

Author

Masetti, C., primary, De Leonardis, F., additional, Rossi, P., additional, Bosa, A., additional, Di Paolo, D., additional, Milana, M., additional, Santopaolo, F., additional, Pecchioli, A., additional, Di Nardi, S., additional, Francioso, S., additional, Lenci, I., additional, Baiocchi, L., additional, Brega, A., additional, Antenucci, F., additional, Marianelli, T., additional, and Angelico, M., additional

Published
2017
Full Text
View/download PDF

38. The challenge of HCV-retreatment after DAA-failure: Italian real-life from VIRONET-C network

Author

Cento, V., primary, Barbaliscia, S., additional, Di Maio, V.C., additional, Masetti, C., additional, Minichini, C., additional, Magni, C.F., additional, Micheli, V., additional, Marenco, S., additional, Nicolini, L.A., additional, Bruzzone, B., additional, Troshina, Y., additional, Baiguera, C., additional, Dentone, C., additional, Calvaruso, V., additional, Paolucci, S., additional, Melis, M., additional, Aragri, M., additional, Bertoli, A., additional, Lenci, I., additional, Landonio, S., additional, Schiavini, M., additional, Sticchi, L., additional, Ruggiero, T., additional, Polilli, E., additional, Messina, V., additional, Pellicelli, A., additional, Boglione, L., additional, Cozzolongo, R., additional, Biolato, M., additional, Morisco, F., additional, Siciliano, M., additional, Parruti, G., additional, Barbarini, G., additional, Craxì, A., additional, Babudieri, S., additional, Puoti, M., additional, Ciancio, A., additional, Rizzardini, G., additional, Coppola, N., additional, Angelico, M., additional, Perno, C.F., additional, and Ceccherini-Silberstein, F., additional

Published
2017
Full Text
View/download PDF

39. Multiclass HCV resistance to interferon-free direct acting antivirals regimens in real life failures advocates for tailored second-line therapies

Author

Di Maio, V.C., primary, Cento, V., additional, Lenci, I., additional, Aragri, M., additional, Barbaliscia, S., additional, Francioso, S., additional, Paolucci, S., additional, Melis, M., additional, Verucchi, G., additional, Masetti, C., additional, Coppola, N., additional, Magni, C.F., additional, Micheli, V., additional, Pollicino, T., additional, Ruggiero, T., additional, Landonio, S., additional, Mancon, A., additional, Starace, M., additional, De Leonardis, F., additional, Santopaolo, F., additional, Bertoli, A., additional, Antonucci, F.P., additional, D’Ambrosio, C., additional, Calvaruso, V., additional, Sorbo, M.C., additional, Morisco, F., additional, Pasquazzi, C., additional, Maida, I., additional, Picciotto, A., additional, Di Biagio, A., additional, Bruzzone, B., additional, Sticchi, L., additional, Ghisetti, V., additional, Cozzolongo, R., additional, Romagnoli, D., additional, Boccaccio, V., additional, Grieco, A., additional, Vecchiet, J., additional, D’Ettorre, G., additional, Merli, M., additional, Gaeta, G.B., additional, Ciancio, A., additional, Marinaro, L., additional, Polilli, E., additional, Cacciatore, P., additional, Andreone, P., additional, Barbarini, G., additional, Gulminetti, R., additional, Novati, S., additional, Pace Palitti, V., additional, Tarquini, P., additional, Puoti, M., additional, Sangiovanni, V., additional, De Stefano, G., additional, Giorgini, A., additional, Paoloni, M., additional, Caporaso, N., additional, Babudieri, S., additional, Gubertini, G., additional, Bruno, S., additional, Andreoni, M., additional, Pellicelli, A., additional, Parruti, G., additional, Raimondo, G., additional, Baldanti, F., additional, Rizzardini, G., additional, Craxì, A., additional, Angelico, M., additional, Perno, C.F., additional, and Ceccherini-Silberstein, F., additional

Published
2017
Full Text
View/download PDF

40. Liver stiffness and portal hypertension predict failure to DAA treatment in a real-life cohort of HCV-infected patients treated with recommended regimens

Author

Masetti, C., primary, De Leonardis, F., additional, Rossi, P., additional, Bosa, A., additional, Di Paolo, D., additional, Milana, M., additional, Santopaolo, F., additional, Pecchioli, A., additional, Di Nardi, S., additional, Francioso, S., additional, Lenci, I., additional, Baiocchi, L., additional, Brega, A., additional, Marianelli, T., additional, Antenucci, F., additional, and Angelico, M., additional

Published
2017
Full Text
View/download PDF

41. Decreased alpha-fetoprotein levels in HCV cirrhotic patients after direct-acting antiviral agents therapy. Does this indicate a reduced risk of hepatocellular carcinoma?

Author

De Leonardis, F., primary, Masetti, C., additional, Rossi, P., additional, Di Paolo, D., additional, Bosa, A., additional, Milana, M., additional, Santopaolo, F., additional, Cucchiarelli, S., additional, Pecchioli, A., additional, Francioso, S., additional, Lenci, I., additional, Brega, A., additional, Marianelli, T., additional, Antenucci, F., additional, Di Nardi, S., additional, Baiocchi, L., additional, and Angelico, M., additional

Published
2017
Full Text
View/download PDF

42. Treatment with direct-acting antiviral agents is associated with improvement of renal function in a cohort of hepatitis C virus infected patients with chronic kidney disease

Author

Masetti, C., primary, De Leonardis, F., additional, Rossi, P., additional, Bosa, A., additional, Di Paolo, D., additional, Milana, M., additional, Santopaolo, F., additional, Pecchioli, A., additional, Di Nardi, S., additional, Francioso, S., additional, Lenci, I., additional, Baiocchi, L., additional, Brega, A., additional, Antenucci, F., additional, Marianelli, T., additional, and Angelico, M., additional

Published
2017
Full Text
View/download PDF

43. The challenge of HCV-retreatment after DAA-failure: real-life experience advocates for caution

Author

Cento, V., primary, Barbaliscia, S., additional, Di Maio, V.C., additional, Masetti, C., additional, Minichini, C., additional, Magni, C.F., additional, Micheli, V., additional, Marenco, S., additional, Nicolini, L.A., additional, Bruzzone, B., additional, Troshina, Y., additional, Baiguera, C., additional, Dentone, C., additional, Calvaruso, V., additional, Paolucci, S., additional, Melis, M., additional, Aragri, M., additional, Bertoli, A., additional, Lenci, I., additional, Landonio, S., additional, Schiavini, M., additional, Sticchi, L., additional, Ruggiero, T., additional, Polilli, E., additional, Messina, V., additional, Pellicelli, A., additional, Boglione, L., additional, Cozzolongo, R., additional, Biolato, M., additional, Morisco, F., additional, Siciliano, M., additional, Parruti, G., additional, Barbarini, G., additional, Craxì, A., additional, Babudieri, S., additional, Puoti, M., additional, Ciancio, A., additional, Rizzardini, G., additional, Coppola, N., additional, Angelico, M., additional, Perno, C.F., additional, and Ceccherini-Silberstein, F., additional

Published
2017
Full Text
View/download PDF

44. Optimization of direct antiviral agent treatment schedule in hepatitis C virus genotype 3 infection: an Italian, multicentetric experience in real-life setting

Author

Granata, R., primary, Valvano, M.R., additional, Donnarumma, L., additional, Camera, S., additional, Milella, M., additional, Andreone, P., additional, Messina, V., additional, Termite, A.P., additional, Cozzolongo, R., additional, Santantono, T., additional, Tundo, P., additional, Ciracì, E., additional, Masetti, C., additional, Smedile, A., additional, Morando, F., additional, Morisco, F., additional, Caporaso, N., additional, and Andriulli, A., additional

Published
2017
Full Text
View/download PDF

45. Liver stiffness and portal hypertension predict failure to DAA treatment in a real-life cohort of hepatitis C virus-infected patients treated with recommended regimens

Author

Masetti, C., primary, De Leonardis, F., additional, Rossi, P., additional, Bosa, A., additional, Di Paolo, D., additional, Milana, M., additional, Santopaolo, F., additional, Pecchioli, A., additional, Di Nardi, S., additional, Francioso, S., additional, Lenci, I., additional, Baiocchi, L., additional, Brega, A., additional, Antenucci, F., additional, Marianelli, T., additional, and Angelico, M., additional

Published
2017
Full Text
View/download PDF

46. Hepatitis C virus clearance after direct-acting antivirals in cirrhotic patients by stages of liver impairment: the ITAL-C network study

Author

Ippolito, A.M., primary, Milella, M., additional, Messina, V., additional, Conti, F., additional, Cozzolongo, R., additional, Morisco, F., additional, Brancaccio, G., additional, Barone, M., additional, Santantonio, T., additional, Fasano, M., additional, Masetti, C., additional, Tundo, P., additional, Smedile, A., additional, Carretta, V., additional, Gatti, P., additional, Termite, A.P., additional, Valvano, M.R., additional, Bruno, G., additional, Fabrizio, C., additional, Andreone, P., additional, Zappimbulso, M., additional, Gaeta, G.B., additional, Napoli, N., additional, Fontanella, L., additional, Lauletta, G., additional, Cuccorese, G., additional, Metrangolo, A., additional, Francavilla, R., additional, Ciracì, E., additional, Rizzo, S., additional, and Andriulli, A., additional

Published
2017
Full Text
View/download PDF

47. Clinical and functional changes associated with the sustained virological response after treatment of genotype-1 HCV recurrence in liver transplant recipients: Does sofosbuvir differ from peg-interferon based therapy?

Author

Lenci, I., primary, Milana, M., additional, Santopaolo, F., additional, Rossi, P., additional, Francioso, S., additional, Masetti, C., additional, Di Paolo, D., additional, Cucchiarelli, S., additional, De Leonardis, F., additional, Bosa, A., additional, Angelico, M., additional, and Baiocchi, L., additional

Published
2016
Full Text
View/download PDF

48. Treatment failure to first-line direct antiviral (DAA) in HCV-related advanced liver disease: An Italian real-life urban setting

Author

Di Paolo, D., primary, Rossi, P., additional, Lenci, I., additional, Milana, M., additional, Masetti, C., additional, Santopaolo, F., additional, Lionetti, R., additional, D’Offizi, G., additional, Pellicelli, A., additional, Fondacaro, L., additional, Siciliano, M., additional, Gerardi, V., additional, Chiesara, F., additional, Moretti, A., additional, Ceccherini-Silberstein, F., additional, Cento, V., additional, Perno, C.F., additional, and Angelico, M., additional

Published
2016
Full Text
View/download PDF

49. Failure to First-Line Direct Antiviral (DAA) Treatment of HCV Infection in an Italian Real-Life Urban Setting

Author

Di Paolo, D., primary, Rossi, P., additional, Lenci, I., additional, Milana, M., additional, Masetti, C., additional, Santopaolo, F., additional, Lionetti, R., additional, D’Offizi, G., additional, Pellicelli, A., additional, Fondacaro, L., additional, Siciliano, M., additional, Tortora, A., additional, Chiesara, F., additional, Moretti, A., additional, Ceccherini-Silberstain, F., additional, Cento, V., additional, Perno, C.F., additional, and Angelico, M., additional

Published
2016
Full Text
View/download PDF

50. Clinical and Functional Changes Associated with the Achievement of Sustained Response in HCV Genotype-1 Infected Liver Transplant Recipients: Does Sofosbuvir Differ from Peg-Interferon Therapy?

Author

Lenci, I., primary, Milana, M., additional, Santopaolo, F., additional, Rossi, P., additional, Francioso, S., additional, De Leonardis, F., additional, Di Paolo, D., additional, Cucchiarelli, S., additional, Masetti, C., additional, Angelico, M., additional, and Baiocchi, L., additional

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results